Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Pancreatic Neoplasms 679Carcinoma, Non-Small-Cell Lung 324Neoplasms 168Breast Neoplasms 163Urinary Bladder Neoplasms 157Lung Neoplasms 157Neoplasm Metastasis 139Cholangiocarcinoma 112Ovarian Neoplasms 106Biliary Tract Neoplasms 92Lymphoma, Large B-Cell, Diffuse 73Nasopharyngeal Carcinoma 70Lymphoma 66Sarcoma 63Recurrence 62Gallbladder Neoplasms 60Carcinoma, Transitional Cell 55Triple Negative Breast Neoplasms 54Hodgkin Disease 52Colorectal Neoplasms 49Fallopian Tube Neoplasms 48Lymphoma, Non-Hodgkin 47Adenocarcinoma 45Bile Duct Neoplasms 40Carcinoma, Ovarian Epithelial 31Non-Muscle Invasive Bladder Neoplasms 30Uterine Cervical Neoplasms 28Carcinoma 28Unspecified Adult Solid Tumor, Protocol Specific 27Adenocarcinoma of Lung 27

Interventions

toripalimab 1sapanisertib 1potassium oxonate 1gimeracil 1apatinib 1Tegafur 1Nivolumab 1MLN 8237 1Gemcitabine 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Malignant Neoplasms of Digestive Organs × Gemcitabine × Clear all
NCT05934331 2025-09-12

A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study

LaNova Medicines Limited

Phase 2 Recruiting
276 enrolled
Other neoplasm

Malignant Neoplasms of Digestive Organs

Data powered by HemOnc (CC BY 4.0) Colophon âš¡